We’re at the Dawn of the Ozempic Era — and It’s Really Weird
About this episode
The central question is how the arrival of GLP-1 drugs like Ozempic, Wegovy, and Zepbound will reshape medicine, food, and society. Belluz argues the drugs are genuinely transformative — the first effective medical treatment for obesity, with benefits extending to diabetes, heart disease, addiction, and possibly dementia — but their debut is 'weird': pricing and supply gaps, shortages forcing rationing for diabetes patients, a flood of compounded knockoffs, and open questions about long-term effects and whether people must take them for life. She cautions against moralizing food noise and stresses the evidence base — randomized trials, animal data, and the consistent finding that these drugs lower the body's weight set point. The conversation also covers the food environment that drives obesity, the possibility of pills replacing injections, and the equity risks if insurers and the government do not cover a drug that mostly benefits the affluent.